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Amyotrophic lateral sclerosis (ALS) is a fatal neurode-
generative disease characterized by the progressive
loss of motor neurons. While several pathogenic
mutations have been identified, the vast majority of
ALS cases have no family history of disease. Thus,
for most ALS cases, the disease may be a product
of multiple pathways contributing to varying degrees
in each patient. Using machine learning algorithms,
we stratify the transcriptomes of 148 ALS postmor-
tem cortex samples into three distinct molecular sub-
types. The largest cluster, identified in 61% of patient
samples, displays hallmarks of oxidative and proteo-
toxic stress. Another 19% of the samples shows
predominant signatures of glial activation. Finally, a
third group (20%) exhibits high levels of retrotranspo-
son expression and signatures of TARDBP/TDP-43
dysfunction. We further demonstrate that TDP-43 (1)
directly binds a subset of retrotransposon transcripts
and contributes to their silencing in vitro, and (2) path-
ological TDP-43 aggregation correlates with retro-
transposon de-silencing in vivo.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal progressive neuro-
degenerative disorder with no known cure, and only two Food
and Drug Administration (FDA)-approved treatments that appear
to mildly slow disease progression. ALS is a largely sporadic dis-
ease, with 90% of patients carrying no known genetic mutation1164 Cell Reports 29, 1164–1177, October 29, 2019 ª 2019 The Auth
This is an open access article under the CC BY-NC-ND license (http://or family history of disease. Large-scale patient sequencing
studies have identified a growing number of genes in which mu-
tations are linked to ALS (Chia et al., 2018; Nicolas et al., 2018;
van Rheenen et al., 2016). The most common ALS-associated
mutations are repeat expansions in the intronic region of
C9orf72, while mutations in well-known ALS-associated genes
such as SOD1 and TARDBP are typically present in fewer than
2% of all ALS patients (Chia et al., 2018).
Mutations in the TARDBP gene (that generates the TDP-43
protein) are rare in ALS, yet nearly all ALS patients exhibit cyto-
plasmic aggregates of TDP-43 in the affected tissues (Arai et al.,
2006; Neumann et al., 2006). TDP-43 has known roles in RNA
splicing, stability, and small RNA biogenesis (Cohen et al.,
2011). Recently, several studies have suggested that TDP-43
also plays a role in regulating the activity of retrotransposons
(Chang and Dubnau, 2019; Krug et al., 2017; Li et al., 2015; Saldi
et al., 2014). Retrotransposons, a subset of transposable ele-
ments (TEs), are genomic parasites capable of inserting new
copies of themselves throughout the genome by a process
called retrotransposition. Previous work from our lab and others
has shown that TDP-43 represses retrotransposon transcripts at
the RNA level in animal models of TDP-43 pathology (Krug et al.,
2017; Li et al., 2012). However, a role for TDP-43 in general retro-
transposon silencing has not been demonstrated, nor whether
TDP-43 pathology in ALS patients correlates with retrotranspo-
son de-silencing. Of note, prior studies have identified a link be-
tween retrotransposon expression and repeat expansion in
another ALS-linked gene, C9orf72 (Prudencio et al., 2017).
Finally, contrasting studies either failed to find an enrichment
for elevated levels of the endogenous retrovirus HERV-K in a
smaller sample of ALS tissues (Mayer et al., 2018) or suggested
that TDP-43 may activate HERV-K transcription rather than
silencing this particular retrotransposon (Li et al., 2015). Theseor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
studies left open the question of whether retrotransposon
silencing is a conserved role for TDP-43 and whether retrotrans-
poson de-silencing would be expected in human tissues with
TDP-43 dysfunction.
Here, we show that robust retrotransposon de-silencing
occurs in a distinct subset of ALS patient samples, and this
is associated with TDP-43 dysfunction. Unbiased machine
learning algorithms identified three distinct ALS patient molecu-
lar subtypes within the large ongoing sequencing survey by the
NYGC ALS Consortium. These subtypes represented both ALS
disease-implicated signatures as well as additional correlated
pathways. The largest subgroup of patients (61%) showed evi-
dence of oxidative and proteotoxic stress. A second subgroup
(19%) displayed strong signatures of glial activation and inflam-
mation. A third subgroup (20%) wasmarked by retrotransposon
re-activation as a dominant feature. We further validated the
correlation between TDP-43 pathology and retrotransposon
de-silencing in a second independent cohort of postmortem
tissue samples, which also recapitulated the three distinct
molecular subtypes. These subtypes may reflect different pre-
dominant aberrant cellular mechanisms contributing to ALS
pathogenesis, and thus suggest specific therapeutic strategies
may have greater relevance to distinct sets of sporadic ALS
patients.
RESULTS
Evidence for Distinct Molecular Subtypes in ALS Patient
Samples
The NYGC ALS Consortium has gathered deeply sequenced
transcriptomes from the frontal cortex of 77 ALS patients as
well as 18neurological andnon-neurological controls (Figure 1A).
For some patients, multiple samples were taken from various re-
gions of the frontal cortex, including motor cortex, such that 148
total transcriptomes were available from ALS patients, while 28
were from controls (176 samples in all) (Table S1A). Most of these
patients presented with sporadic ALS disease (i.e., no known
family history or pathogenic mutation) consistent with general
estimates that ALS as a disease is largely sporadic (Chia et al.,
2018).
The large size of this dataset enables de novo clustering algo-
rithms to determine whether the ALS patient samples fall into
distinct molecular subsets defined by specific gene signatures.
We used a recent method for de novo clustering that was origi-
nally developed for single-cell sequencing datasets, but has
been equally validated on bulk transcriptomes, single-cell RNA
sequencing (RNA-seq) analysis and klustering evaluation
(SAKE) (Ho et al., 2018). SAKE, developed by our group, is based
on non-negative matrix factorization (NMF) and can robustly es-
timate both the number of clusters present in a given dataset and
the confidence in assigning each sample to a cluster. SAKE re-
turned optimal results for 3 clusters within the NYGC ALS Con-
sortium Cohort (Figure S1), and a heatmap of the genes that
define these clusters is given in Figure 1B. Based on the sets
of gene markers returned by the SAKE algorithms, some of
which are labeled on the left hand side of Figure 1B (see also
Table S2A), we have chosen to re-label the 3 ALS subtypes as
ALS-TE (elevated transposable element, or TE, expression, redin Figure 1B), ALS-Ox (oxidative stress markers, blue), and
ALS-Glia (elevated glial markers, gold).
The largest subset of patient samples in the NYGC survey
(91/148) were marked by elevated levels of several genes previ-
ously associated with ALS. These included NEFH, SOD1, and
CDH13 (Chia et al., 2018), as well as a general expression signa-
ture consistent with oxidative and proteotoxic stress. These
samples are identified as ALS-Ox (Figure 1B, blue). ALS-Ox pa-
tient samples showed elevated levels of genes in the oxidative
phosphorylation pathway, in pathways associated with Parkin-
son’s disease, as well as proteotoxic stress pathways as deter-
mined by Gene Set Enrichment Analysis (GSEA) (Figure 1C;
Table S2B). Surprisingly, these samples also showed enrichment
for genes previously noted to be elevated in both mutant SOD1
(Chiu et al., 2013) and TREM2-dependent (Keren-Shaul et al.,
2017) models of disease associated microglia (Figure 1C),
although microglial markers were not specifically enriched in
these samples (Table S2B).
A second subset of patient samples, dubbed ALS-Glial (Fig-
ure 1B, gold), is defined by increased expression of genes
that mark astrocytes (CD44, GFAP) and oligodendrocytes
(MOG, OLIG2) suggesting that glial markers were a dominant
signature in the transcriptomes of these samples. The ALS-Glial
subset of patient samples also showed strong enrichment for
transcriptional signatures previously identified as marking
disease-associated microglia in either a mutant SOD1 (Chiu
et al., 2013) or TREM2-dependent model (Keren-Shaul et al.,
2017) (Figure 1C; Table S2C) and in levels of TREM2 expression
(Figure 1D). Finally, these patients also showed upregulation of
innate immune pathways that are typically elevated in activated
microglia, such as interferon and antigen processing pathways
(Figure 1C).
Retrotransposon transcripts form a subset of the genes that
define the remaining ALS samples, ALS-TE, named for transpos-
able elements (TEs). These patient samples (Figure 1B, red) rep-
resented 20% (29/148) of the samples in the NYGC cohort. The
ALS-TE samples showed an enrichment for transposon expres-
sion as the most significantly enriched pathway relative to con-
trols using GSEA pathway analysis (Figure 1C; Table S2D), and
this included TEs from the long interspersed element (LINE),
short interspersed element (SINE), and long terminal repeat
(LTR) classes. The samples in the ALS-TE subset also showed
depletion for components of the spliceosome and for protein
export pathways, two pathways previously linked to normal
TDP-43 function (Cohen et al., 2011). Finally, violin plots of indi-
vidual transposable elements, such as the LINE element L1PA6,
show increased transposon levels for specific retrotransposons
(Figure 1D). The fact that unbiased and unsupervised clustering
identified several individual TEs as specifically defining this
group provides a rigorous and quantitative method of deter-
mining the samples in which TE expression is well above the
normal control levels and unique to this subset of ALS patients.
As stated above, multiple frontal and motor cortex tissues
were sampled for a subset of ALS patients, allowing for an esti-
mation of the level of concordance of ALS subtype between
different tissues for the same patient. Of the 40 patients with
both frontal and motor cortex samples sequenced, we note
that only 7 were discordant between the two tissues (17.5%),Cell Reports 29, 1164–1177, October 29, 2019 1165
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Figure 1. ALS Patients in the NYGC ALS Consortium Cohort Show 3 Distinct Subtypes: Retrotransposon Reactivated (ALS-TE), Oxidative
Stress Signatures (ALS-Ox), and Glial Dysfunction (ALS-Glial)
(A) A schematic depiction of cortical regions from which post-mortem tissue samples were obtained: 148 from ALS patients, 11 from patients with other
neurological disorders, and 17 from subjects. Multiple samples were obtained for most patients, such that these samples represent 77 ALS patients, 6
neurological control subjects, and 12 healthy controls.
(B) A heatmap of gene expression in ALS patient samples showing the results of NMF-based clustering, which returned 3 robust and distinct groups of patients.
The retrotransposon reactivated set showed high TE expression as a dominant signature and formed its own subgroup (ALS-TE), representing 20% of all patient
samples. Two additional groups were identified that showed signatures of oxidative stress (ALS-Ox, 61% of samples), and glial dysfunction (ALS-Glial, 19% of
samples). Representative gene sets that describe markers from each subset are identified along the left of the heatmap.
(C) Gene Set Enrichment Analysis was performed for each group of patients (ALS-TE, ALS-Ox, and ALS-Glial) versus controls to identify group-specific aberrant
pathways.
(D) Violin plots of example markers for each group show the LINE retrotransposon L1PA6 marking the ALS-TE group, SOD1 marking the ALS-Ox group, and
TREM2 marking the ALS-Glial samples.
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Figure 2. ALS-Ox Patients in the NYGC ALS Consortium Show Markers of Oxidative Stress
(A) The ALS-Ox group represents the middle 61% of patient samples in the ALS Consortium set (outlined in blue), with ALS-Ox marker genes listed along the left-
hand side of the heatmap.
(B) Violin plots of example markers for this group show two known ALS-associated genes, MATR3 and NEFL, specifically elevated in the ALS-Ox group (blue
violins).
(legend continued on next page)
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suggesting a high degree of overlap between these two tissues
(Table S1B).
The ALS-Ox Group Displays Evidence of Oxidative
Stress
The importance of oxidative stress in neurodegenerative disease
began with the initial identification of superoxide dismutase 1
(SOD1) as the first ALS-associated mutation (Rosen et al.,
1993). Subsequent studies have identified a diverse array of
functional pathways altered in SOD1 mutant mouse models,
including SOD1 mediated autophagy (Rudnick et al., 2017), pro-
teotoxic stress (Bruijn et al., 1998), and neuroinflammation (Chiu
et al., 2013), reflecting both the pleiotropic roles played by SOD1
protein as well as different manifestations depending on the
cellular context in which SOD1 is dysfunctional. Since that initial
discovery, several genes with roles in oxidative stress, proteo-
toxic stress, and autophagy have been linked to ALS (Taylor
et al., 2016). Consistent with the importance of these pathways,
and their linked nature in generating neuronal stress, we found
that 61% of the NYGC ALS patient samples displayed gene
expression signatures consistent with a robust response to
oxidative and proteotoxic stress, as described below.
Samples in the ALS-Ox group show elevated levels of several
stress response genes, mutations in which have been linked to
ALS, including SOD1 itself (Figures 1D and 2A), as well as the
neurofilament protein NEFL and the nuclear matrix protein
MATR3 (Figure 2B). More generally, the pathways that are
elevated in the ALS-Ox samples relative to controls include
genes involved in oxidative phosphorylation, proteasomal com-
ponents, and genes involved in the unfolded protein response
(Figure 2C). This subset of patients also displayed elevated
expression of several genes that have been previously associ-
ated with multiple neurodegenerative diseases including both
ALS and Parkinson’s disease, such that these disease pathways
are also significantly enriched in the ALS-Ox group relative to
controls (Figure 2C; Table S2B).
To further validate these results, we obtained fresh frozen mo-
tor cortex tissue for an additional set of 13 ALS patients and 6
non-neurological controls, provided by a tissue bank at the
University of California, San Diego (UCSD) (Table S1C). Two
biological replicate transcriptomes were sequenced from each
patient and control tissue sample to ensure the results would
be robust to within-patient heterogeneity. We note that the
RNA-seq libraries for the UCSD cohort were prepared at a
different site, using a different library preparation protocol
(please see Method Details), and yet these patient datasets dis-
played similar groupings to those from the NYGC cohort. We
quantitatively assigned these samples to each of the ALS sub-
type groups, by combining the two groups (NYGC and UCSD)
into a single principal components analysis (PCA) (Figure 2D).
Patients were assigned to a subtype based on the distance to(C) Top enriched pathways identified by GSEA in the ALS-Ox group samples co
(D) Additional ALS patient samples from UCSD are assigned to the NYGC ALS s
in blue).
(E) To confirm the link between ALS-Ox membership and stress pathways, indiv
expression of genes in the Oxidative Stress pathway (OXR1, TXN), ER-linked prot
autophagy (ATG5, TBK1).
1168 Cell Reports 29, 1164–1177, October 29, 2019each cluster centroid on the PCA graph, with most samples fall-
ing within the 95% confidence interval ellipse defining the NYGC
group (Figure S2A). Two of the 13 ALS patients from this UCSD
cohort fell within the ALS-Ox group, with 2 samples plotted per
patient to show concordance between biological replicates.
Consistent with their classification, we noted that these patient
samples also displayed similar expression patterns for all ALS-
Oxmarker genes, comparable to that seen in the NYGC samples
(Figure S2B, gray bars). We next performed qPCR expression
analysis on all UCSD patient samples for a selection of genes
whose dysregulation characterized each of the three molecular
subtypes (Figure S2C). While the number of patient samples
here is small relative to the larger NYGC cohort, corresponding
significant differences were validated for NEFL (p < 0.01) and
ATG5 (p < 0.03) compared to controls. BECN1 showed milder
differences that did not reach statistical significance compared
to controls (p < 0.3) but shows a similar trend relative to other
ALS cortex samples as that seen in the larger NYGC survey
(Figure S2C).
The relative positions on the PCA plot in Figure 2D represent
the expression of genes underlying the oxidative and proteotoxic
stress responses in both patient cohorts. This is confirmed by
the individual PCA plots of specific marker genes in Figure 2E,
in which the color intensity of each dot indicates the expression
level. For the oxidative stress pathway, expression is shown for
oxidation resistance 1 (OXR1) and thioredoxin (TXN). For the pro-
teotoxic stress response pathway, expression is shown for ubiq-
uilin-2 (UBQLN2) and beclin-1 (BECN1). Finally, for markers of
autophagy, expression is shown for autophagy gene 5 (ATG5)
and TANK binding kinase (TBK1). We note that these 3 pathways
are typically linked, such that both oxidative stress and proteo-
toxic stress have been noted to induce an autophagic response
in neurodegenerative disease (Wong and Holzbaur, 2015),
consistent with these pathways showing elevation in the same
subset of samples. Thus, these results are consistent with ALS
patient samples in the ALS-Ox group mounting a robust
response to several neuronal stressors, which may be concur-
rent in the tissue.
The Predominance of Glial Markers in the ALS-Glia
Group
Several recent studies have noted the important role that glial
cells play in neurodegenerative disease. Astrocytes, cells that
support neuronal function by providing nutrients and removing
waste, have previously been shown to secrete neurotoxic factors
when expressing ALS-associated mutations (Di Giorgio et al.,
2007; Nagai et al., 2007). Microglia, the innate immune cells of
the CNS, have been shown to become activated in several
neurodegenerative diseases (Deczkowska et al., 2018), setting
off a neuroinflammatory cascade that eventually results in motor
neuron cell death. In the ALS Consortium Cohort, 19% of thempared to controls.
ubgroups by position on this PCA plot (UCSD samples marked by patient ID
idual PCA plots are shown where each sample is colored by the normalized
eotoxic stress pathways (UBQLN2, BECN1), and downstream genes related to
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ALS patient samples showed extensive evidence of glial involve-
ment, as discussed below.
Samples in the ALS-Glial subgroup show elevated expression
of markers for all glial cell types, including astrocytes (CD44,
GFAP), microglia (IBA1/AIF1, TREM2), and oligodendrocytes
(OLIG1, OLIG2, MOG), as noted on the heatmap of Figure 3A.
Violin plots are shown in Figure 3B for specific genes marking
microglial (IBA1) and astrocyte (CD44) cell types in each of the
ALS patient samples, with a particular enrichment in ALS-Glial
subtype patients (gold). In particular, some of the microglial
markers most prominently elevated in these samples represent
genes known to be expressed in activated microglia and associ-
ated with neurodegenerative disease, such as IBA1 (Figure 3B)
and TREM2 (Figure 1D). Consistent with this, pathway analysis
of the genes that are upregulated in ALS-Glial samples relative
to controls include mediators of the inflammatory response in
general, the interferon response in particular, and other genes
downstream of the tumor necrosis factor alpha (TNF-a) signaling
pathway (Figure 3C). Two recent reports have identified gene
expression signatures of disease-associated microglia (DAM)
in mouse models of neurodegeneration carrying mutations in
either SOD1 (Chiu et al., 2013) or TREM2 (Keren-Shaul et al.,
2017). These two DAM gene expression signatures were also
strongly enriched in the ALS-Glia cortex samples relative to con-
trols (Figure 3C; Table S2C).
One underlying mechanism that could explain profiles in the
ALS-Glia samples is a relative loss of motor neurons, and/or
increased presence of glial cells in these particular tissues. We
used software designed to infer the relative composition of
different cell types in bulk tissues, NeuroExpresso (Mancarci
et al., 2017), to determine whether there was any evidence of
differential cell type enrichment in the ALS-Glial samples. The
NeuroExpresso results support this possibility, with estimates
of cellular composition showing an increase in markers of
activated microglia (p < 0.003) as well as oligodendrocytes (p <
0.002) and astrocytes (p < 0.02) (Figure S3A) relative to controls.
These patients also showed the strongest signatures for relative
loss of neuronal markers from both the pyramidal (p < 6.7e7)
and GABAergic (p < 3.1e5) classes. We next obtained
formalin-fixed paraffin-embedded (FFPE) slides matched to 35
of the decedents included in the NYGC cohort. These included
7 decedents from the ALS-Glia cluster, 9 decedents each from
the ALS-TE and ALS-Ox clusters, and 6 controls. We performed
immunohistochemistry for themicroglial protein IBA1 (Figures 3F
and S3B). While IBA1 marks all microglia (resting and activated),Figure 3. ALS-Glia Patients in the NYGC ALS Consortium Cohort Show
(A) The ALS-Glia group represents the 19% of patient samples on the right side
genes listed along the left side of the heatmap.
(B) Violin plots of example markers for this group show two known glial marker g
violins).
(C) Top enriched pathways identified by GSEA in the ALS-Glia group samples co
(D) Additional ALS patient samples from UCSD are assigned to the NYGC ALS s
in gold).
(E) To confirm the link between ALS-Glia membership andmarkers of particular gli
normalized expression of genes that mark Microglia (IBA1, TREM2), Oligodendro
(F) To confirm the link between ALS-Glia membership and activated microglia, U
show presence of enlarged, activated microglia not seen in controls or other ALS
indicating a size of 50–70mm.
1170 Cell Reports 29, 1164–1177, October 29, 2019we note that activated microglia are distinguished by more
intense IBA1 staining and have enlarged cell bodies (diameters
of 70 mm for activated versus 30 mm for resting, Figure S3B).
Using these parameters, we quantified activated microglia in
cortical layer sections.We find a spectrum in the rate of activated
versus resting microglia in the cortex (Figure S3B) and found the
highest rates of activated microglia in the cortex of decedent
samples corresponding to the ALS-Glia cluster (Figure S3B).
These moderate increases in activated microglia could be asso-
ciated with neuronal cell loss in these tissues. To address this
possibility, wemeasured cell density by counting all of the hema-
toxylin positive nuclei in each sample (Figure S3C). There were
no significant differences between ALS subtypes and controls,
and no decrease in cell number per mm2 in the ALS-Glia pa-
tients, in particular. This suggests that the ALS-Glia transcrip-
tome patterns are driven by activated transcription of glial cell
associated pathways rather than relative loss of neuronal cells.
In the UCSD tissue validation cohort, 4/13 ALS patient sam-
ples clustered with the NYGC ALS-Glial group, without strong
evidence of transposon de-silencing or oxidative stress markers
(gold markers labeled by patient ID in the PCA plot of Figure 3D).
These samples also showed elevated levels of TREM2 and IBA1
expression, at levels similar to that in the NYGC samples (Fig-
ure 3E). Moreover, markers of oligodendrocytes were also
strongly enriched in this group, including OLIG1 and MOG.
Finally, astrocyte markers were also present in these ALS-Glia
samples, but were largely absent from samples in the ALS-TE
and ALS-Ox groups, with GFAP and CD44 shown as representa-
tives (Figure 3E). Validation by qPCR in the UCSD cohort,
confirmed a significant enrichment for ALS-Glia markers in these
patients relative to controls (Figure S2C): TREM2 (p < 0.001),
MOBP (p < 0.001), and IBA1 (p < 0.01).
The ALS-TE Group Displays Altered Expression of
Genes in Multiple Pathways Linked to TDP-43
Sporadic ALS patients are known to show cytoplasmic accumu-
lation and aggregation of TDP-43 protein (produced by the
TARDBP gene) in the motor cortex and spinal cord, two tissues
where motor neuron loss occurs (Arai et al., 2006; Neumann
et al., 2006). Such TDP-43 pathology is thought to cause both
a loss of the normal function of TDP-43 as well as aggregation
associated detrimental impact. Thus, TDP-43 targets would be
expected to be mis-regulated in ALS patients with TDP-43
pathology and an associated loss of TDP-43 nuclear function.
Previous studies have linked TDP-43 to roles in splicing, mRNAEvidence of Disease-Associated Microglia
of the ALS Consortium set (outlined in gold), with additional ALS-Glia marker
enes, AIF1/IBA1 and CD44, specifically elevated in the ALS-Glia group (gold
mpared to controls.
ubgroups by position on this PCA plot (UCSD samples marked by patient ID
al subsets, individual PCA plots are shownwhere each sample is colored by the
cytes (OLIG1, MOG), and astrocytes (GFAP, CD44).
CSD patient samples were stained with antibodies to IBA1. ALS-Glia samples
subgroups. Images are shown at 20 3 magnification, with labeled scale bars
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Figure 4. ALS-TE Patients in the NYGC ALS Consortium Cohort Show Retrotransposon Re-activation
(A) The ALS-TE group represents the left hand 20%of patients in the ALS Consortium sample set (outlined in Red), with ALS-TEmarkers listed along the left-hand
panel.
(B) Violin plots of example markers for this group show two relatively young retrotransposons, L1HS and SVA_A, and TARDBP expression.
(C) Top enriched pathways identified by GSEA in the ALS-TE versus controls.
(D) Additional ALS samples from UCSD are assigned to the defined subgroups by position on this PCA plot (UCSD samples marked by patient ID in red).
(E) To confirm the link between ALS-TE membership and TDP-43 pathology, UCSD patient samples were stained with antibodies to the phosphorylated form of
TDP-43 (pTDP-43, left) as well as with antibodies that recognize full-length TDP-43 protein (right). ALS-TE samples show evidence of pTDP-43 pathology not
present in controls or other ALS subgroups. Images are shown at 20 3 magnification, with labeled scale bars indicating a size of 50mm.metabolism, and protein export (Cohen et al., 2011), as well as
retrotransposon silencing (Krug et al., 2017; Li et al., 2012).
Consistent with this last role, several retrotransposons from the
endogenous retrovirus (ERV), LINE, and SINE-VNTR-Alu (SVA)
class were selected as specifically marking the ALS-TE group(Figure 4A). High levels of individual retrotransposons, including
TEs from the LINE and SVA class (Figure 4B), characterize this
group, while retrotransposons in general formed the top en-
riched pathway in GSEA (Figure 4C). Additional pathways
depleted from the ALS-TE group are also consistent withCell Reports 29, 1164–1177, October 29, 2019 1171
previously identified functional roles for TDP-43, including pro-
tein export, the spliceosome, and proteasomal components
(Figure 4C). Finally, we note that TARDBP expression levels
are the lowest in the ALS-TE group overall (Figure 4B), which
could be mediated by TDP-43 auto-regulation (Ayala et al.,
2011) or other mechanisms.
We again turned to samples from the UCSD patient cohort for
follow up analysis and validation. Seven UCSD ALS decedents
fell within the ALS-TE group, with patient ID marked in red on
Figure 4D. Consistent with their PCA-based classification (Fig-
ure S2A), we noted that these UCSD patient samples also dis-
played elevated levels of TEs, comparable to that seen in the
NYGC samples (Figure S2B). This was validated using qPCR
for three specific retrotransposons that are known to be young
and active in human genomes (Mills et al., 2007): the human
specific LINE1 element (L1HS, p < 0.05) and two young SINE
elements of the Alu class, AluYk12 (p < 0.001) and AluYa5
(p < 0.001) (Figure S2C).
To establish a more direct link between the ALS-TE group and
TDP-43 pathology, we stained slides from both the NYGC and
UCSD decedent samples described above with an antibody
directed against phosphorylated TDP-43, which has been previ-
ously characterized to identify patients with TDP-43 pathology in
ALS (Neumann et al., 2009). The ALS-TE samples with elevated
TE expression levels and loss of known TDP-43 pathway genes
are the most likely to show TDP-43 inclusion pathology in the
frontal and motor cortex (p < 0.035), as shown for representative
fields in Figure 4E and quantified in Figure S3D. Control samples
did not show evidence of pTDP-43 inclusions in the tissues
analyzed (Figure S3D), and non-ALS-TE samples did not exhibit
transcriptional patterns consistent with established TDP-43
regulated pathways (Tables S2B and S2C). Together, these re-
sults establish a correlation between TDP-43 dysfunction and
transcriptional re-activation of retrotransposon sequences in
ALS patient tissues. The underlying basis for this will be explored
next.
TDP-43 Functions to Silence Retrotransposons
While pathways linked to oxidative stress and activated glia have
previously been linked to ALS and other neurodegenerative dis-
eases (Taylor et al., 2016), a potential role for retrotransposons in
ALS is only recently emerging. As such, we used a genomics
approach in neuronal-like cell lines to bolster the connection be-
tween retrotransposon expression and the function of the ALS
associated protein TDP-43. TDP-43 is an RNA binding protein
with two RNA recognition domains that recognize UGUGU
repeat motifs present in thousands of cellular RNAs (Polymeni-
dou et al., 2011; Tollervey et al., 2011). Previous TDP-43 studies
using fly (Krug et al., 2017; Li et al., 2012) and human (Li et al.,
2012) models to identify downstream targets of TDP-43 have
suggested that retrotransposons may form a subset of TDP-43
targets, either directly or indirectly, but the extent and functional
impact of this was not fully understood. To establish the subset
of direct TDP-43 target genes and retrotransposons, we
sequenced the RNAs bound to TDP-43 protein using an
enhanced cross-linking and immunoprecipitation protocol
(eCLIP-seq) (Van Nostrand et al., 2016) in human SH-SY5Y neu-
roblastoma cells. Peaks were called using a CLIP-seq analysis1172 Cell Reports 29, 1164–1177, October 29, 2019tool designed for handling repetitive reads, CLAM (Zhang and
Xing, 2017). Results from two biological replicates of TDP-43
eCLIP libraries were merged and normalized to a cross-linked,
size-matched input control, resulting in 36,716 called peaks
mapping to 5770 genes and 439 transposable elements (Fig-
ure 5; Tables S3A and S3B). Thirty-one percent of all peaksmap-
ped to transposable elements generally (Figure 5B). However,
58% of the TE associated peaks mapped to the opposite strand,
suggesting the TEs were providing regulatory sequence for the
host gene, a phenomenon previously observed for other RNA
binding proteins (Attig et al., 2018; Kelley et al., 2014; Zarnack
et al., 2013). The remaining 42%, which were directly bound to
TEs in the sense orientation, can be grouped into three major
families, encompassing LINE elements (5% of all called peaks),
SINE elements (4% of peaks), and LTR regions that include
endogenous retroviruses (2%). Verification that these sequences
were directly bound to TDP-43 protein was supported by the
presence of TDP-43 binding motifs at called peaks in both the
gene and retrotransposon annotated peaks (Figure 5C; Table
S3C). Examples of TDP-43 CLIP reads over a known gene target
(TARDBP/TDP-43) as well as retrotransposon targets from
each major class (LINE, L1PA6; SINE, AluY; LTR, HERV3;
SVA, SVA_D) can be seen in Figured 5A and 5D with a full list
in Table S3B. The gene targets correlate well with previously
identified TDP-43 targets from CLIP-seq and RIP-seq studies
(Colombrita et al., 2012; Polymenidou et al., 2011; Tollervey
et al., 2011; Van Nostrand et al., 2016; Xiao et al., 2011), which
previously missed transposon targets due to masking of repeti-
tive regions or discarding of ambiguously mapped reads.
Together, these results demonstrate that TDP-43 normally binds
broadly to both gene and TE-derived transcripts. This compre-
hensive list of direct targets in SH-SY5Y cells provides a platform
to investigate the impact of TARDBP knock down on expression
of target RNAs.
To determine the subset of CLIP targets that are regulated at
the transcript abundance level, we knocked down the levels of
TDP-43 protein using a short hairpin RNA strategy (TDP-43kd).
The TDP-43kd construct strongly reduced TARDBP mRNA
expression and TDP-43 protein level (Figure 5G). We sequenced
the transcriptomes of both control and TDP-43kd libraries. All
significantly altered retrotransposon transcripts were upregu-
lated in TDP-43kd cells, indicating that TDP-43 normally contrib-
utes to the silencing of retrotransposon transcripts (Figure 5E;
Table S3D). This is in contrast to altered gene transcripts, where
a substantial fraction was either up- (1,165 genes, 34%) or
downregulated (2,246 genes, 66%) in TDP-43kd cells (Figure 5F;
Table S3D). Moreover, a majority of the directly bound gene tar-
gets were downregulated in the absence of TDP-43 (52%). This
is consistent with known roles for TDP-43 in contributing to alter-
native splicing or translation control for a large fraction of gene
targets that are not regulated at themRNA abundance level (Pol-
ymenidou et al., 2011; Tollervey et al., 2011). However, the fact
that nearly all expressed retrotransposon transcripts were upre-
gulated in the absence of TDP-43 suggests that TDP-43 plays a
silencing role for transposons. This is consistent with previous
studies of the role of TDP-43 in the fly brain (Krug et al., 2017)
and conclusively link directly bound TDP-43 transposon targets
with the regulation of these targets at the expression level.
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Figure 5. TDP-43 Binds and Regulates Retrotransposon Transcripts
(A) A schematic of the eCLIP-seq based identification (2 biological replicates) of directly bound RNA targets for TDP-43, with a representative pileup of reads
where TDP-43 is known to target its own 30 UTR.
(B) A pie chart of annotation categories for TDP-43 targets shows that retrotransposons are a small but important fraction of direct targets (12.9%). Gene intronic
sequences represent the largest fraction of all peaks at 44%, while an additional 17.6% represent regions where TEs provide regulatory sequences to the host
gene intron.
(C) The known TDP-43 binding motif (UGUGU) is present in both gene and retrotransposon targets.
(D) Representative browser pileup plots for one retrotransposon from each major repeat class: an L1PA6 LINE element, an AluY SINE element, a HERV3 LTR
element, and an SVA_D from the human specific SVA class.
(E) Knock down of TDP-43 levels (2 biological replicates) results in the upregulation of retrotransposon transcripts, most of which also show evidence for direct
binding in the eCLIP-seq experiments (gray bars).
(F) A volcano plot of fold change versus false discovery rate (FDR) q values shows that upregulated TEs (red dots) form a substantial fraction of all TDP-43
dependent genes, and all are upregulated.
(G) Knock down efficiency of short hairpin RNAs (shRNAs) targeting TARDBP was validated by western blot analysis and qPCR. For RNA levels, replicates were
averaged and SD shown as error bars. For protein levels, western blots of the two biological replicates are shown separately.Clinical Parameter Association with ALS Subtype
We investigated whether clinical/phenotypic variables correlate
with the three ALS molecular subtypes identified in this study.
As shown in Figure S4, there was no statistically significant asso-
ciation between any of the groups and sex, C9ORF72 repeat
expansion status, age at death, age at onset, or disease dura-
tion. Patients with limb onset were more frequently associated
with the ALS-TE subtype than expected (Fisher’s exact p <0.03), however, there was no relative depletion of ALS-TE patient
samples among those with bulbar onset symptoms. No signifi-
cant differences in overall survival were found between the iden-
tified subtypes, as shown by Kaplan-Meier survival curves for
each group (Figure S4G).
Genotyping was performed to assess the distribution of pa-
tients carrying germline repeat expansions in C9orf72. Hexanu-
cleotide repeat expansions in the intron of C9orf72 are theCell Reports 29, 1164–1177, October 29, 2019 1173
most common pathogenic alterations associated with the devel-
opment of ALS, both familial and sporadic (Majounie et al., 2012).
Moreover, previous studies have noticed a slight trend toward
higher TE expression in patients carrying C9orf72 mutations
(Pereira et al., 2018; Prudencio et al., 2017; Zhang et al., 2019).
In order to determine if patients carrying aC9orf72 repeat expan-
sion are overrepresented in one or several of the identified ALS
subtypes, genotyping of the hexanucleotide repeat size was
performed on the NYGC cohort (Table S1B). C9orf72 repeat
expansion carriers were neither significantly over- nor underrep-
resented in the ALS-TE (p = 1) or ALS-Glia patients (p < 0.65).
However, we observed a non-significant trend toward exclusion
of C9orf72 repeat expansion carriers among the ALS-Ox sam-
ples (p < 0.09). We note that none of the patient samples from
the UCSD validation cohort carried repeat expansions in
C9orf72 (Table S1C), although each of the ALS subtypes was
represented in this group (Figure S2B; Table S1C). Together,
this suggests that C9orf72 repeat expansions are not driving
the transcriptional profiles of these subgroups but may be asso-
ciated with patterns typically not seen in patients of the ALS-Ox
group.
DISCUSSION
De novo discovery of transcriptome subtypes from a large ALS
cortex tissue sequencing study demonstrated that ALS cortex
samples fall into three distinct clusters. The pathways that define
two of these subtypes (oxidative and proteotoxic stress and neu-
roinflammation) have a well-established association with ALS
disease, while a third subtype showed highly elevated retro-
transposon expression. While genetic mutations are rare in
ALS disease, pathogenic mutations can be grouped generally
into those that largely mediate protein homeostasis, RNA meta-
bolism, and neuroinflammation (Taylor et al., 2016), although
many genes are linked to more than one of these processes.
An example is SOD1, which has been ascribed roles in oxidative
stress (Rosen et al., 1993), proteotoxic stress (Bruijn et al., 1998),
and microglial activation (Chiu et al., 2013). While multiple
cellular stressors might be contributing to the disease, we found
that each decedent sample could be grouped into one of three
molecular clusters, which largely reflected pathways already
described for ALS, but which fell into surprisingly distinct groups.
Specifically, 60% of the patient samples exhibited gene expres-
sion markers suggesting oxidative stress and proteotoxic stress
were the main contributors to cellular dysfunction (the ALS-Ox
group) but did not show elevated markers of glial cell types or in-
ferred glial cell enrichment in the tissue downstream of these
stress responses. Only 20% of the patients showed extensive
glial involvement (the ALS-Glial group), with an unknown mech-
anism initiating the activation of glial cells for these patients in
particular.
The role of transposable element expression is a relatively new
topic in the study of neurodegeneration. Moreover, the connec-
tion between TDP-43 and transposable elements has only
recently been explored. While previous studies have linked
TDP-43 to transposon binding in human cells and to transposon
regulation in animal models (Chang and Dubnau, 2019; Krug
et al., 2017; Li et al., 2015; Liu et al., 2019), we show that TDP-1174 Cell Reports 29, 1164–1177, October 29, 20194-bound transposon transcripts are de-silenced in human cells
and demonstrate that these same targets are de-silenced in a
subset of human ALS patients. Additional mechanisms for trans-
poson de-silencing in ALS patients with C9orf72 repeat expan-
sions have been suggested (Pereira et al., 2018; Prudencio
et al., 2017; Zhang et al., 2019), although we note that C9orf72
status was not strongly associated with the ALS-TE group in
this study. Together, this suggests a model where retrotranspo-
son silencing is a normal function of TDP-43 in somatic cells, and
this role is disrupted in ALS patient tissues, potentially contrib-
uting to cellular toxicity. Previous studies have demonstrated
that expression of envelope proteins from the endogenous retro-
virus class of retrotransposons can be toxic to cells of the CNS
(Antony et al., 2004; Kremer et al., 2013; Li et al., 2015). Addi-
tional studies have shown that expressed retrotransposon
RNAs can also be toxic through aberrant recognition by innate
immune components in Aicardi-Goutières syndrome (Crow and
Manel, 2015). Other studies linked transposon activation in
Alzheimer’s disease with tau aggregation and suggest these al-
terations accompany neuroinflammation and genomic instability
(Guo et al., 2018; Sun et al., 2018). DNA damage and structural
variants induced by transposition itself are a formal possibility,
given the elevated levels of the fully competent LINE-1Hs retro-
transposon and evidence for active L1Hs transposition in human
neurons (Evrony et al., 2016; Upton et al., 2015). However, most
of the retrotransposons expressed in this study derived from
fixed elements that have lost the capacity to transpose. These
and other mechanisms for retrotransposon contributions to
cellular toxicity remain to be explored in ALS patients but present
a possible mechanism for cellular damage in the subset of pa-
tients with extensive TDP-43 pathology and retrotransposon
re-activation.
Finally, the three subgroups defined in this study were identi-
fied from postmortem tissues of a largely sporadic set of patients
with no known family history of the disease. Thus, ALS subtype
appears to be largely independent from genotype. Transcrip-
tional differences that separate these subtypes may reflect mul-
tiple contributing factors including causal mechanisms, disease
progression stage, cellular composition of the tissues due to loss
of particular cell types, and differences in environmental interac-
tions that contribute to onset. The fact that transcriptional
profiles of post mortem cortex tissues segregate into three
distinct groupings may provide an entry point to investigate
these underlying mechanisms. If peripheral tissues amenable
to sampling or biopsy (e.g., peripheral blood monocytes, cere-
brospinal fluid, or muscle) have distinct molecular signatures
that correlate with patterns found in these CNS tissue sub-
groups, it could facilitate cohort selection for clinical trials of ther-
apies targeting specific pathogenic mechanisms. Indeed, the
existence of distinct clusters of sporadic ALS patients—whether
based on intrinsic pathogenic differences or disease stage—
might explain why many treatments identified in laboratory
models targeting a specific pathway have failed to translate to
successful clinical trials. Additional correlations may arise as
the ALS Consortium genomic data cohort continues to grow.
These additional studies will allow for an exploration of whether
glial activation in the CNS correlates with general inflammation
outside of CNS tissues.
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Anti-GAPDH antibody Cell Signaling Technology Cat# 5174, RRID:AB_10622025
Anti-IBA1 antibody EnCor Biotechnology Cat# RPCA-IBA1, RRID:AB_2722747
Anti-phospho-TARDBP antibody (pS409/410) Cosmo Bio Co., Ltd Cat# TIP-PTD-M01, RRID:AB_1961900
Anti-TARDBP antibody Proteintech Group Cat# 10782-2-AP, RRID:AB_615042
Anti-alpha-tubulin antibody CSHL monoclonal antibody
collection
Clone DM1A, RRID:AB_5216186
HRP-linked anti-mouse IgG Cell Signaling Technology Cat# 7076, RRID:AB_330924
HRP-linked anti-rabbit IgG Cell Signaling Technology Cat# 7074, RRID:AB_2099233
Biological Samples
Postmortem frontal and motor cortex samples from
ALS patients and unaffected individuals
NYGC ALS Consortium N/A
Postmortem motor cortex samples from ALS patients
and unaffected individuals
UCSD N/A
Critical Commercial Assays
AmplideX PCR/CE C9ORF72 Kit Asuragen Cat# 49581
Bolt 4-12% Bis-Tris Plus Gel ThermoFisher Scientific Cat# NW04120BOX
PowerUp SYBR Green Master Mix ThermoFisher Scientific Cat# A25741
SuperSignal West Pico PLUS Chemiluminescent Substrate ThermoFisher Scientific Cat# 34577
Deposited Data
NYGC ALS Consortium RNA-seq datasets GEO GEO: GSE124439
UCSD ALS RNA-seq datasets GEO GEO: GSE122650
TARDBP knockdown in SH-SY5Y cell line GEO GEO: GSE122650
TARDBP eCLIP in SH-SY5Y cell line GEO GEO: GSE122650
Experimental Models: Cell Lines
SH-SY5Y cell line ATCC Cat# CRL-2266, RRID:CVCL_0019
HEK293FT cell line ThermoFisher Scientific Cat# R70007, RRID:CVCL_6911
Oligonucleotides
See Table S4 N/A
Recombinant DNA
MISSION pLKO.1-puro Human TDP-43/TARDBP shRNA plasmid Genetic Perturbation Platform ID# TRCN0000016038
MISSION pLKO.1-puro Luciferase shRNA Control Plasmid Sigma Aldrich Cat# SHC007
MISSION pLKO.1-puro Non-Target shRNA Control Plasmid DNA Sigma Aldrich Cat# SHC016
psPAX2 Gift from Didier Trono RRID:Addgene_12260
pMD2.G Gift from Didier Trono RRID:Addgene_12259
Software and Algorithms
CLAM v1.1.3 Zhang and Xing, 2017 https://github.com/Xinglab/CLAM
DESeq2 v1.22.2 Love et al., 2014 RRID:SCR_015687
GSEA v3.0 Subramanian et al., 2005 RRID:SCR_003199
QuPath Bankhead et al., 2017 https://qupath.github.io/
SAKE v1.0 Ho et al., 2018 https://github.com/naikai/sake
STAR v2.5.2b Dobin et al., 2013 RRID:SCR_015899
TEtranscripts (TEToolkit) v2.0.3 Jin et al., 2015 https://github.com/mhammell-
laboratory/tetoolkit
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LEAD CONTACT AND MATERIALS AVAILABILITY
Immediate access to new and ongoing data generated by the NYGC ALS Consortium and obtained from samples collected through
the Target ALS post-mortem core can be requested at ALSData@nygenome.org. All RNA-seq data in the NYGC ALS Consortium are
made immediately available to all members of the Consortium and with other Consortia with whom we have a reciprocal sharing
arrangement. Further information and requests for resources and reagents generated outside of the NYGC ALS Consortium should
be directed to Molly Gale Hammell (mhammell@cshl.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
ALS Post-mortem Samples
The NYGC ALS Consortium samples in this study, the majority provided by the Target ALS Post-Mortem Tissue Core, were acquired
through various IRB protocols from member sites and transferred to NYGC in accordance with all applicable foreign, domestic,
federal, state, and local laws and regulations for processing, sequencing, and analyses. All available de-identified clinical and path-
ological recordswere collected and used together with C9orf72 genotypes to summarize patient demographics and disease features
(see Tables S1A and S1B).
UCSD samples were obtained from patients who had been followed during the clinical course of their illness and met El Escorial
criteria for definite ALS. These individuals had bulbar or arm onset of disease and caudally progressing disease. Control nervous
systems were from patients from the hospital’s critical care unit when life support was withdrawn. IRB approval was obtained
from the University of California, San Diego Human Research Protection Program. All available de-identified patient data is available
in Table S1C.
Cell Line
SH-SY5Y cells (CRL-2266, ATCC, Manassas, VA, USA) were grown in DMEM/F-12 Dulbecco’s Modified Eagle Medium/Nutrient
Mixture F-12 (11320033, ThermoFisher Scientific, Waltham, MA, USA) supplemented with 10% FBS and 1% penicillin–
streptomycin, and cultured at 37C with 5% CO2.
HEK293FT cells (R70007, ThermoFisher Scientific, Waltham, MA, USA) were grown in DMEM medium containing 10% FBS, and
cultured at 37C with 5% CO2.
METHOD DETAILS
Generation of RNA-seq Libraries from NYGC ALS Samples
RNA was extracted from flash-frozen patient samples homogenized in Trizol (15596026, ThermoFisher Scientific, Waltham, MA,
USA) -Chloroform and purified using the QIAGEN RNeasy Mini kit (74104, QIAGEN, Germantown, MD, USA). RNA was assessed
using the Bioanalyzer (G2939BA, Agilent, Santa Clara, CA, USA). RNA-seq libraries were prepared from 500 ng of total RNA using
the KAPA Stranded RNA-seq kit with RiboErase (07962304001, Kapa Biosystems, Wilmington, MA, USA) for rRNA depletion and
Illumina compatible indexes (NEXTflex RNA-seq Barcodes, NOVA-512915, PerkinElmer, Waltham, MA, USA). Pooled libraries
(average insert size: 375bp) were sequenced on an Illumina HiSeq 2500 using a paired end 125 nucleotide setting, to yield
40-50 million reads per library.
Generation of RNA-seq Libraries from UCSD ALS Samples
RNA was extracted from each of the flash-frozen patient samples using the Ambion PureLink RNAMini kit (12183020, ThermoFisher
Scientific, Waltham, MA, USA). RNA was assessed using the Bioanalyzer to ensure RNA Integrity (RIN) values of > = 5.5. RNA-seq
libraries were prepared from 500 ng of total RNA using the Illumina TruSeq Stranded Total RNA kit (20020596, Illumina, San Diego,
CA, USA). Samples were barcoded to multiplex 8 samples per batch, randomly mixing ALS and control samples in each library
preparation and sequencing batch. The libraries were sequenced on an Illumina NextSeq using a single end 76 nucleotide setting,
and pooled to ensure 40 million reads per library.
shRNA Knockdown and Assessment of Efficiency
The MISSION pLKO.1-puro human TDP-43 (TRCN0000016038, Genetic Perturbation Platform) and control shRNAs, SHC007 lucif-
erase shRNA and SHC016 Non-target shRNA control (Sigma Aldrich, St. Louis, MO, USA), were used to produce lentivirus. The
pLKO.1 plasmid DNA, together with psPAX2 packaging and pMD2.G envelope plasmid DNA (Didier Trono lab, Addgene plasmid
# 12260 and 12259 respectively) were combined at a ratio of 4:3:1, respectively and transfected with PEI reagent (23966-1,
Polysciences, Warrington, PA, USA) into HEK293FT cells. Virus containing medium was collected 48 and 72 hours post-transfection
and stored at 80C.Cell Reports 29, 1164–1177.e1–e5, October 29, 2019 e2
One and a half to two million SH-SY5Y cells per well of a 6-well plate were ‘‘spinfected’’ with 3 mL of virus containing media and
8mg/mL polybrene for 1 hour at 800 g. Cells stably expressing shRNAswere selected with 2 mg/mL of puromycin 48 hours post-infec-
tion for 3 days. Uninfected cells at similar density were used as a control for puromycin selection. Cells were harvested 5 days after
infection for downstream analyses.
TDP-43 protein level was assessed by western blot analysis on two biological replicates of SH-SY5Y cells treated with the TDP-
43kd construct or control shRNAs (SHC007 luciferase shRNA or SHC016 Non-target shRNA control) as described above. In brief,
15 mg of protein was electrophoresed on a Bolt 4%–12% Bis-Tris Plus Gel (NW04120BOX, ThermoFisher Scientific, Waltham,
MA, USA), and transferred to nitrocellulosemembrane. Primary antibodies specific for TDP-43 (10782-2-AP, Proteintech, Rosemont,
IL, USA, 1:3,000), alpha-tubulin (Clone DM1A, provided by the CSHL monoclonal antibody collection, Cold Spring Harbor, NY, USA,
1:3000) andGAPDH (5174, Cell Signaling Technology, Danvers, MA, USA, 1:1000) were used. Protein detection was performed using
HRP-linked secondary antibodies (7074 and 7076, Cell Signaling Technology, Danvers, MA, USA, 1:10000), and Super Signal West
Pico PLUS Chemiluminescent Substrate (34577, ThermoFisher Scientific, Waltham, MA, USA).
Knockdown efficiency of TARDBP transcript was assessed by quantitative PCR, performed in triplicate on two biological replicates
of SH-SY5Y cells treated with the TDP-43kd construct or control shRNAs (SHC007 luciferase shRNA or SHC016 Non-target shRNA
control) as described above. Total RNA was extracted using Trizol according to the manufacturer’s instructions from the harvested
cells. qPCR reactions were made with the PowerUp SYBR Green Master Mix according to the manufacturers’ instructions (A25741,
ThermoFisher Scientific, Waltham, MA, USA), and run on a QuantStudio 6 Flex instrument (ThermoFisher Scientific, Waltham, MA,
USA). Primers for TARDBP and GAPDH were obtained from PrimerBase (Spandidos et al., 2010). Please see Table S4 for more
details on the primers used.
RNA-seq in SH-SY5Y Cells
Total RNA was extracted using Trizol according to the manufacturer’s instructions from two biological replicates of SH-SY5Y cells
treated with the TDP-43kd construct or control shRNAs (SHC007 luciferase shRNA or SHC016 Non-target shRNA control) as
described above. One microgram of total RNA was subjected to rRNA removal using the Ribo-Zero Gold rRNA Removal kit
(MRZG126, Illumina, San Diego, CA, USA). Strand specific RNA-seq libraries were constructed using NEBNext Ultra II Directional
Library Prep Kit (E7760S, New England Biosciences, Ipswich, MA, USA). The libraries were sequenced on an Illumina NextSeq using
a single end 76 nucleotide setting, and pooled to ensure 40 million reads per library.
TARDBP/TDP-43 eCLIP in SH-SY5Y Cells
Twenty million SH-SY5Y cells were UV-crosslinked (254 nm, 400mJ/cm2) in PBS and cell pellets were stored at80C. Each sample
was prepared as an independent biological replicate and included non-crosslinked cells as a control. Cell pellets were lysed in 1 mL
lysis buffer, followed by RNase I digestion and immunoprecipitation with 10 mg of anti-TDP-43 antibody (10782-2-AP, Proteintech,
Rosemont, IL, USA).
eCLIP libraries were prepared as previously described (Van Nostrand et al., 2016). In brief, a barcoded adaptor is ligated to the
30 end, and the precipitated RNA-protein complex is separated on nitrocellulose. The complex is digested with proteinase K and
the RNA is precipitated and reverse-transcribed using SuperScript IV first strand synthesis system (18091050, ThermoFisher
Scientific, Waltham, MA, USA). A second adaptor is ligated on the 50 end, and the libraries were sequenced on an Illumina
NextSeq500 using a single end 76 nucleotide setting.
Histology and Immunohistochemistry
Frozen motor cortex tissues were fixed in 10% neutral buffered formalin and 5 mm paraffin sections were cut for immunohistochem-
istry (IHC) staining. IHC staining was performed on Ventana Discovery Ultra platform with OmniMap HRP and ChromoMap DAB
detection system according to manufacturer’s protocols (Roche, Indianapolis, IN, USA), using primary antibodies specific for
TDP-43 (10782-2-AP, Proteintech, Rosemont, IL, USA, 1:10,000), phosphoTDP-43 (pS409/410) (CAC-TIP-PTD-M01, Cosmo Bio
USA, Co., Carlsbad, CA, 1:200) and IBA1 (RPCA-IBA1, EnCor Biotechnology Inc., Gainesville, FL, 1:2,000). Slides were counter-
stained with Hematoxylin, and then scanned by Leica Aperio ScanScope system.
Genotyping of C9orf72 Repeat Expansion
NYGC patient samples were genotyped for C9orf72 repeat expansions using a combination of cross-repeat fragment size analysis,
standard repeat-primed PCR, and the Asuragen AmplideX PCR/CE C9ORF72 Kit (49581, Asuragen, Austin, TX, USA).
UCSD patient samples were genotyped for C9orf72 repeat expansions using standard repeat-primed PCR, as previously
described (Renton et al., 2011). Briefly, primers outside the C9orf72 intronic repeats were amplified in a nested PCR strategy, and
the resulting traces were analyzed on a Bioanalyzer to determine repeat length.
qPCR Analysis of UCSD Patient Samples
Quantitative PCR of UCSD samples was carried out in triplicate on two biological replicates each, using PowerUp SYBR Green
Master Mix according to the manufacturers’ instructions (A25741, ThermoFisher Scientific, Waltham, MA, USA), and run on a
QuantStudio 6 Flex instrument (ThermoFisher Scientific, Waltham, MA, USA). Primers for AIF1/IBA1, ATG5, BECN1, GAPDH,e3 Cell Reports 29, 1164–1177.e1–e5, October 29, 2019
MOBP, NEFL and TREM2 were obtained from PrimerBank (Spandidos et al., 2010). Primers for RPS24 were obtained from Sigma
Aldrich (H_RPS24_1, Sigma Aldrich, St. Louis, MO, USA). Previously published primers for L1HS 50 UTR (Macia et al., 2017), AluYa5
and AluYk12 (Prudencio et al., 2017) were used for quantification of these transposable elements.
Please refer to Table S4 for more details on the primers used.
QUANTIFICATION AND STATISTICAL ANALYSIS
Analysis of RNA-seq Libraries
Reads from samples with RIN > = 5.5 were aligned to the hg19 human genome using STAR v2.5.2b (Dobin et al., 2013), allowing for a
4% mismatch rate and up to 100 alignments per read to ensure capture of young transposon sequences. Abundance of gene and
transposon sequences was calculated with TEtranscripts v2.0.3 (Jin et al., 2015). For differential expression analysis, we employed
DESeq2 (Love et al., 2014), using the DESeq normalization strategy and negative binomial modeling. B-H corrected FDR P value
threshold of p < 0.05 was used to determine significance. For heatmap visualization, the reads were normalized using a variance
stabilizing transformation in DESeq2.
Transcriptome De Novo Cluster Identification
The number of clusters in the ALS datasets was determined using the SAKE software suite (Ho et al., 2018). Briefly, a variance sta-
bilizing transformation was performed on the raw counts data using DESeq2. Gender associated genes were then removed from this
list before rank ordering by median absolute deviation using the SAKE software suite, selecting the top 5000 genes with the highest
median absolute deviation (MAD). SAKE was implemented using 200 iterations, the ‘‘nsNMF’’ algorithm for Non-negative Matrix
Factorization, and a ‘‘k’’ setting of 3 clusters for the cortex samples, determined by the k setting with the highest cophenetic corre-
lation coefficient. WilcoxonMannWhitney U-tests were used to determine differences between ALSSubgroups and correlations with
gene expression or cell type composition.
Classification of UCSD Samples using NYGC-identified Clusters
Variance stabilizing transformation was performed on the raw counts of NYGC and UCSD data using DESeq2. Principal component
analysis was then performed to identify principal components that delineate the identified ALS subtypes, and a 95% confidence
ellipse was calculated from the NYGC samples for each subtype. The position of the UCSD patient samples along the principal
components of interest was determined as the midpoint of the two replicates, and a distance to the center of the 95% confidence
ellipse for each subtype was calculated. The UCSD samples were classified based on the nearest ellipse center of the subtype.
Gene Set Enrichment Analysis
Pre-generated gene sets used for GSEA (Subramanian et al., 2005) were obtained from the MSigDB Hallmark collection (Liberzon
et al., 2015), and KEGG (Kanehisa and Goto, 2000). Custom gene sets were generated from the SOD1 (Chiu et al., 2013) and
TREM2 (Keren-Shaul et al., 2017) models of disease-associatedmicroglia, as well as TARDBP targets from this study. Custom trans-
posable element sets, including retrotransposons considered active in the human genome (Mills et al., 2007) were generated from
Repbase (Bao et al., 2015).
Analysis of eCLIP Libraries
Reads were trimmed to remove adapters, and aligned to the hg19 human genome using STAR v2.5.2b (Dobin et al., 2013), allowing
for a 4% mismatch rate and up to 100 alignments per read to ensure capture of young transposon sequences. Weighting of
multi-mapper alignments (expectation-maximization modeling) and identification of regions of enrichment relative to input (using
negative binomial modeling) were performed with CLAM v1.1.3 (Zhang and Xing, 2017). Detected sites with B-H corrected FDR
P value of p < 0.05 were considered to be significantly enriched. Integrated genome viewer (Robinson et al., 2011) was used for
visualization of enriched regions and read depth.
Analysis of IHC Tissue Slides
Images were exported from the Leica Aperio ScanScope and analyzed using the QuPath image analysis software v 0.2.0-m2 (Bank-
head et al., 2017). Upper cortical regions within 1.5mm of the outer cortical surface of the tissue that were of good quality (minimal
damage or non-specific staining) were chosen as regions of interest. Cell nuclei were detected in the regions of interest using
Hematoxylin optical density (minimum nuclear area of 15mm2, but otherwise default settings). Cells positive for phosphorylated
TDP-43 accumulation were identified as having mean nuclear DAB optical density above 0.75. Activated microglia were designated
as cells with nuclear area of at least 70mm2, and amean nuclear DAB optical density above 0.7. Proportions of positive cells (pTDP-43
or activated microglia) were calculated. Cell density in regions of interest was determined by dividing the number of detected nuclei
by the area of the regions of interest. Wilcoxon Mann Whitney U-tests were used for comparison of pTDP-43/IBA1 positive cell
proportions and cell density between ALS Subgroups and control samples.Cell Reports 29, 1164–1177.e1–e5, October 29, 2019 e4
qPCR Data Analysis
Quantitative PCR results of UCSDpatient samples were analyzed using theDDCtmethod, normalized toGAPDH andRPS24. Knock-
down efficiency of TDP-43kd construct was determined using the DDCt method, normalized to GAPDH. TARDBP transcript levels
are expressed relative to the SHC007 transfected samples. A Student’s t test was used to determine statistical significance.
Analysis of Clinical Parameters
Fisher’s Exact test was used to determine enrichments of patient gender and C9orf72 repeat expansion in each ALS subtype.
Differences in age of death (compared to control individuals), age of onset and disease duration (compared between subtypes)
was analyzed using Wilcoxon Mann Whitney U-tests. Survival analysis was performed using Kaplan-Meier log rank test.
DATA AND CODE AVAILABILITY
The accession number for the CSHL Motor Cortex RNA-seq datasets reported in this paper is GEO: GSE122649. The accession
number for the CLIP-seq and RNA-seq datasets fromSH-SY5Y cells reported in this paper is GEO: GSE122650. The accession num-
ber for the RNA-seq datasets generated by the NYGC ALS Consortium reported in this paper is GEO: GSE124439.e5 Cell Reports 29, 1164–1177.e1–e5, October 29, 2019
